Tools
Register Login

biolyon.com

You are here: Home » home
Friday, 15 Dec 2017

biolyon.com

Analysts experts are dazzled by the blockbuster potential of Novartis LCZ696

E-mail Print PDF

The data aren't out yet, but the buzz about Novartis' new late-stage contender for blockbuster status is growing to fever pitch. This morning Leerink opted to add on $3 billion to the pharma giant's forecasted revenue for 2026, concluding that LCZ696 has the distinct potential of becoming a mainstay therapy in the prevention of cardiovascular deaths--even substituting for the generic ACE inhibitors that now dominate the market.

Read more...

Baxter snaps up its hemophilia partner on the verge of a biotech breakup

E-mail Print PDF

Baxter is buying out collaborator Chatham Therapeutics for $70 million, planning to absorb the gene therapy specialist into its growing hemophilia R&D operation as it prepares to separate its drug and device businesses next year.

Read more...

Battered Amarin finally lands a partner for Vascepa

E-mail Print PDF

After a rough go with the FDA sent its shares spiraling downward, Amarin has at last found a partner to help commercialize its fish-oil-derived pill for high triglycerides.

Read more...

Lumena swings for a 75M IPO to bear down on liver diseases

E-mail Print PDF

A month removed from raising $45 million in venture backing, San Diego's Lumena Pharmaceuticals wants $75 million more as it plots a Wall Street debut, piling up cash to advance its two liver treatments.

Read more...

Party drug turned miracle cure for depression spurs hype and stubborn hope

E-mail Print PDF

The notion that a party drug could be repurposed into a "miracle" cure for severe, treatment-resistant depression is an almost irresistible story line in the popular press. And there's no reason why it can't be recycled using results from the same small, short-duration study design that long ago attracted some of the world's largest research organizations still engaged in researching new drugs in one of the most difficult fields in R&D.

Read more...

Page 1 of 79

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »